Kornimate/medical-research-clean huggingface dataset:
indoor air quality and respiratory morbidity in school-aged children with bpd

Conditions: Bronchopulmonary Dysplasia; Chronic Lung Disease of Newborn; Environmental Exposure

Summary: investigators want to learn the role of indoor environmental exposures on respiratory symptoms, and, separately, on lung function deficits in school-aged children with bronchopulmonary dysplasia (bpd).

bronchopulmonary dysplasia (bpd) is the most common respiratory disease affecting children born prematurely and leads to long-term respiratory symptoms and lung function impairment throughout childhood. this study will, evaluate the contribution of indoor sources of respiratory irritants to respiratory health impairment in school-aged children with bpd. state-of-the-art measures of indoor air quality constituents will assess the relationship of nitrogen dioxide (no2), particulate matter (pm2.5), as well as, concentrations of allergens (mold, mouse, cockroach, pet), endotoxin, air temperature and humidity with concurrently measured respiratory symptoms and lung function in a well-characterized cohort of children with bpd. this research will identify specific harmful components of the indoor environment associated with respiratory morbidity and poor lung function in children with bpd. investigators will ask the participants to come in for a one time clinic visit for undergoing procedures as well as answering questions regarding health and home environment. during the 1 year of participation there will also be 2 home assessment visits where investigators will take a sample of the home environment as well record home characteristics.

Eligibility criteria:
inclusion criteria: * children 6-12 yrs old * born \<32 wks gestational age * diagnosis of bpd or \> 28 days of oxygen or respiratory support exclusion criteria: * major airway or chest surgery * physical or mental impairment that will prevent from doing spirometry * plans to move out of state within the next 9 months

Keywords: bpd bronchopulmonary dysplasia children and environment environment bronchopulmonary dysplasia and environment environment and children chronic lung disease of newborn environment and chronic lung disease of the newborn
effect of blue light glasses on screen usage after a concussion in college students

Conditions: Brain Concussion

Summary: premature cessation of screen usage is a common behavior post-concussion, given the taxing nature of a screen-time task. in the academic setting, screen-time is a near unavoidable component, however, complete avoidance of class and screen use may in fact provoke psychological symptoms of anxiety and depression in students, for fear of falling behind in their studies. thus, compensatory measures should be investigated to assist students as they attempt to maintain academic involvement throughout their concussion recovery. blue light blocking glasses have been shown to significantly increase screen-time usage in individuals with post-concussion syndrome, yet these results are only representative of a small portion of the concussion population. thus, we propose investigating whether blue light blocking glasses can prolong screen usage prior to symptom exacerbation, specifically in concussed students that are still within the normal recovery timeframe. this cross-sectional randomized clinical trial will provide further evidence of the utility blue light blocking glasses can offer as a therapeutic tool for students recovering from concussion. we would like to test volunteers from the rochester institute of technology who have been treated by a medical provider within the university's health center. blue light glasses will be worn during a one-time computer reading task while the subject is participating in the study. the total time for the complete the reading task is dependent upon the participant's symptom fluctuations; however, we suspect completion criteria will be met within 20 minutes from beginning. the risks in this study are minimal and results may increase our understanding of therapeutic tools for patients with ocular-driven concussion symptoms.


Eligibility criteria:
inclusion criteria: * full-time student at rit * diagnosed mild traumatic brain injury * between 18-26 years of age * within 3-14 days post-injury exclusion criteria: * any head, neck, or face injury in the 1 year prior to the study (e.g., concussion, eye injury) other than the current injury * history of vestibular or ocular dysfunction\\ * any neurological disorders (e.g., seizure disorders, closed head injuries with loss of consciousness greater than 15 minutes, cns neoplasm, history of stroke) * injury more severe than mild traumatic brain injury (skull fracture, positive ct or mri) * having taken pain medication within 8 hours prior to testing * not able to personally consent * pregnant * deaf or hard of hearing.
evaluating the effect of laser vision surgery, phakic intraocular lens implantation, cataract surgery, and pupil dilation on the iris recognition scanner function of smartphone

Conditions: Cataract; Myopia; Myopic Astigmatism

Summary: this study included patients who visit for refractive surgery (photorefractive keratectomy, photorefractive keratectomy with with corneal collagen cross linking, laser in situ keratomileusis, small incision lenticule extraction), phakic intraocular lens implantation (implantable collamer lens, artiflex), and cataract surgery. patients will be examined whether iris recognition scanner of smartphone works before and after surgery. in addition, before and after pupil dilation (5mm, 6mm, 7mm, 8mm), patients will be examined whether iris recognition scanner of smartphone works well.


Eligibility criteria:
inclusion criteria: * patients who visit for refractive surgery (photorefractive keratectomy, photorefractive keratectomy with with corneal collagen cross linking, laser in situ keratomileusis, small incision lenticule extraction) * phakic intraocular lens implantation (implantable collamer lens, artiflex) * cataract surgery. * age of 20\~90 exclusion criteria: * history of previous ocular or intraocular surgery * glaucoma or ocular hypertension, ocular infection, non-dry eye ocular inflammation, ocular allergy, autoimmune disease * history of iris damage during ocular surgery or previous trauma * wearing contact lenses during the study period * presence of current punctal occlusion * pregnancy, lactating women, and children
ai-assisted insulin titration system on inpatients glucose control

Conditions: Type 2 Diabetes

Summary: this is a multi-center, open-labeled, parallel group, randomized controlled trial to access the effect and safety of the artificial intelligence assisted insulin titration system (incdss) in patients with type 2 diabetes mellitus.

as one of the most common treatments for diabetes inpatients, insulin regimens often vary due to different physicians. since 2016, zhongshan hospital has set up the internet-based glucose management system (igms) to monitor plasma glucose of diabetes patients, and further set up an artificial intelligence assisted insulin titration system (incdss) to recommend insulin regime in 2019. previous single-center clinical trial (nct04053959) have demonstrated the efficacy and safety of incdss in glycemic management in patients with type 2 diabetes. this multi-center study enrolls 120 patients with type 2 diabetes from 20 wards of zhongshan hospital who are on treatment with insulin for at least 3 months. they are randomly allocated into 2 groups at a ratio of 1:1 after screening for the inclusion and exclusion criteria. patients in the intervention group (ai group) receive insulin regimen set by incdss and patients in control group receive insulin regimen recommended by endocrinologists. this study will be conducted in the department of endocrinology, zhongshan hospital,fudan university and consist of a 7-day intervention period. patient allocation will be stratified by hba1c, bmi and previous total insulin doses. the primary endpoint is the fasting plasma glucose level after the 7-days trial period.

Eligibility criteria:
inclusion criteria: * men or women aged 18-99 years old; * inpatients who had been diagnosed with type 2 diabetes; * subjects who are on treatment with insulin for at least 3 months; * hba1c: 7.0%-10.0%. exclusion criteria: * patients who were diagnosed with t1d, gestational diabetes or other specific types of diabetes. * subjects with acute complications of diabetes such as ketoacidosis or hyperglycemic hyperosmolar state; * patients with severe cardiac, hepatic, renal or general diseases; * subjects that are, in the judgement of the investigator, unlikely to comply with the protocol. * absence of informed consent.

Keywords: incdss t2d ai
congenital heart surgery in pediatric patients with beta-thalassemia major

Conditions: Hemolysis

Summary: authors compared incidence of hemolysis on cardiopulmonary bypass surgery for repair of congenital heart disease in pediatric patients between patients with thalassemia major and control group


Eligibility criteria:
inclusion criteria: * pediatric patients with thalassemia major. * pediatric patients with congenital heart disease undergoing surgical repair. exclusion criteria: * known hepatic or renal disease * uncontrolled active hemolytic reaction * emergency surgery * redo surgery
describe the effect of the optimized hemodialysis technique (hdx) with medium cut-off membrane on recovery time and quality of life

Conditions: Terminal Renal Insufficiency

Summary: in this study, the effect of optimizing the dialytic technique using simple questionnaires carried out in clinical routine will be described. more specifically, the conventional dialysis technique will be combined with biofeedback software called hemocontrol™. the recovery time and quality of life of patients who will use a polyethersulfone membrane (revaclear®) and a medium cut-off (mco) membrane (theranova®) will be observed. the main objective is to describe the evolution of recovery time after a dialysis session in conventional hemodialysis (hd) on revaclear® membrane and in so-called optimized hemodialysis (hdx) on mco membrane, theranova®.


Eligibility criteria:
inclusion criteria: * patient, male or female (using contraceptives, if of childbearing age), over 18 years of age * patient on conventional hemodialysis with synthetic membrane for at least 3 months * patient with a recovery time after the dialysis session ≥ 4 hours * informed patient who has signed a written consent to participate in the study * affiliated patient or beneficiary of a social security scheme exclusion criteria: * patient whose seniority of dialysis is less than 3 months * pregnant woman * protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision * patient with severe cognitive impairment * medically unstable or frail patient * patient who did not sign an informed consent form accepting this research (refusal of consent or absence of signature).

Keywords: terminal renal insufficiency
aliskiren combined with losartan in proteinuric, non-diabetic chronic kidney disease

Conditions: Kidney Disease

Summary: study objective: to investigate the potential anti-proteinuric and renoprotective efficacy of aliskiren in addition to losartan in patients at risk of developing end-stage renal disease (esrd) methods: this will be a randomized, double-blind study in which proteinuric, non-diabetic patients with chronic kidney disease (ckd) will be assigned in a 1:1 ratio to one of the following treatment groups for 3 years: * group a: losartan (control arm: conventional treatment)\* * group b: aliskiren plus losartan (intervention arm)\* * with optional addition of other anti-hypertensive agents to achieve an optimal target blood pressure of \<130/80 mmhg.

aliskiren is a direct renin inhibitor that has been shown to reduce proteinuria and retard renal deterioration in type 2 diabetic patients with overt nephropathy. however, it is not known if these therapeutic effects can be extended to nondiabetic chronic renal disease. the current study aims to explore this research question by randomly assigning patients with various stages of chronic renal disease to receive either aliskiren on top of losartan, or continuation of losartan.

Eligibility criteria:
inclusion criteria: * male or female 18 - 80 years of age * presence of nondiabetic ckd stages 3 to 4 as defined by estimated glomerular filtration rate (egfr by 4-variable mdrd equation) as follows: * stage 3: moderate decrease in gfr 30-59 ml/min/1.73 sq.m * stage 4: severe decrease in gfr 15-29 ml/min/1.73 sq.m * ckd is defined as either kidney damage or gfr \ 3 months with variations of less than 30% in the 3 months before screening * early-morning urinary protein-to-creatinine ratio of \>500 mg/g or 57 mg/mmol on at least 2 occasions four weeks apart * patients who are willing to give written, informed consent exclusion criteria: * egfr \ 60 ml/min/1.73m2 * early-morning urinary protein-to-creatinine ratio of \>5000 mg/g or 570 mg/mmol, or urinary protein-to-creatinine ratio of \<500 mg/g or 57 mg/mmol * serum k+ \> 5.2 mmol/l * presence of bilateral renal artery stenosis * known allergy to losartan or aliskiren * patients who are receiving angiotensin ii receptor blocker / angiotensin converting enzyme inhibitor combination within 12 weeks of randomization * concurrent treatment with corticosteroids, nonsteroidal antiinflammatory drugs, or immunosuppressive agent * patients with connective tissue disease or obstructive uropathy * patients with concomitant malignancy or any such conditions that will severely limit life expectancy * female who are pregnant or intending to conceive * female of child-bearing age who are unwilling to practice effective contraception * patients who are unable to give informed consent * patients simultaneously participating in another study or who have participated in another study within the last 30 days of entry into this study

Keywords: ckd proteinuria egfr progression of chronic kidney disease
riluzole in treating patients with stage iii or stage iv melanoma that can be removed by surgery

Conditions: Melanoma (Skin)

Summary: rationale: riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma. purpose: this early phase i trial is studying how well riluzole works in treating patients with stage iii or stage iv melanoma that can be removed by surgery.

objectives: primary * to evaluate the potential effects of glutamate receptor blockade on cellular pathways important in the genesis and progression of melanoma in patients with stage iii or iv melanoma undergoing surgical resection. * to determine whether treatment with riluzole alters expression of activated plc and erk in lysates from tumor tissue biopsies. secondary * determine if treatment with riluzole affects the overall metabolic activity of melanoma tumors as measured by pre- and post-treatment pet scanning, pre- and post-treatment tumor mitotic rate evaluation, and pre- and post-treatment immunohistochemical staining for ki-67. outline: patients receive oral riluzole twice daily for 14 days. within 24 hours after the final dose of riluzole, patients undergo standard surgical resection. patients undergo tumor tissue sample collection at baseline and during surgery for laboratory studies. samples are analyzed by routine histology, immunohistochemistry, western blotting, and rt-pcr for grm1 expression, - ras and b-raf mutations, plc and map kinase activity, ki-67 staining, and mitotic rate. patients also undergo blood sample collection periodically for pharmacokinetics studies. pet scans are obtained before and after treatment to evaluate the overall metabolic activity of the tumor and how this activity changes with inhibition of the grm1 pathway.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed melanoma * stage iii or iv disease * must have at least two resectable tumors or a tumor large enough to undergo pre-treatment core needle biopsy * must be eligible for resection of disease with curative or palliative intent patient characteristics: * ecog performance status 0 or 1 * anc ≥ 1,000/mm³ * platelet count ≥ 50,000/mm³ * ast/alt ≤ 3 times upper limit of normal (uln) * total bilirubin normal * calculated creatinine clearance ≥ 50 ml/min * inr ≤ 25% of uln * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception during and for 48 hours after completion of study treatment * no history of allergic reaction to riluzole or similar compounds * no known history of hepatitis b or c prior concurrent therapy: * not specified

Keywords: stage iii melanoma stage iv melanoma
congenital syphilis prospective cohort with retrospective evaluation

Conditions: Syphilis, Congenital

Summary: syphilis is an infectious disease caused by treponema pallidum. in children, there are two different forms of this disease; acquired syphilis and congenital syphilis, which results from transplacental transmission of spirochetes. the worldwide incidence of congenital syphilis has increased in past years, probably due to inadequate control of pregnant women and lack of early diagnose and treatment in acute infected adults. this infection can have numerous and non-specific manifestations at all stages, and may simulate other diseases, which can delay diagnose if not suspected. a high number of newborns can be asymptomatic, so diagnose is confirmed or discharged by serologic testing after 6 to 10 months of age. this study will observe the clinical presentation and the laboratory of patients with cs treated.


Eligibility criteria:
inclusion criteria: * infants with reactive vdrl /rpr of mothers with positive serology without confirmed treatment or incomplete. * patients with compatible clinical signs of syphils. exclusion criteria: * patients with diagnosis of acquired syphilis * patients whose medical records are missing

Keywords: congenital syphilis vdrl csf clinical manifestations
an open study for steroid resistant, non-thymectomized mg patients

Conditions: Myasthenia Gravis

Summary: the purpose of the study is to investigate the efficacy and safety for steroid resistant, non-thymectomized mg patients.


Eligibility criteria:
inclusion criteria: * clinically diagnosed as myasthenia gravis * those whose mg symptoms are not controlled by the treatment with prednisone exclusion criteria: * those who had undergone thymectomy

Keywords: tacrolimus myasthenia gravis
a therapeutic confirmatory study of epaminurad versus febuxostat in gout patients

Conditions: Gout

Summary: a phase 3 clinical trial to compare and evaluate efficacy and safety of epaminurad with febuxostat in gout patients.


Eligibility criteria:
inclusion criteria: * for screening 1. ≥19 to ≤75 years of age at the time of written informed consent 2. diagnosed record with gout, or acr/eular 2015 score ≥8 3. able and willing to actively participate in tlc programme 4. signed icf for voluntary study participation * for randomization 1. sua level ≥7.0 mg/dl 2. acr/eular 2015 score ≥8 exclusion criteria: 1. medical history malignant tumor, urolithiasis within 5 years, hypersensitivity disease, lesch-nyhan syndrome, hereditary problems, ischemic heart disease, prior or planned organ transplant recipient. 2. concurrent disease or laboratory test abnormality uncontrolled diabetes mellitus, uncontrolled hypertension, uncontrolled dyslipidemia, ast or alt ≥2×uln, total bilirubin ≥1.5×uln, egfr \<30 ml/min/1.73m\^2, uncontrolled thyroid dysfunction, hiv, hbv or hcv positive, drug and alcohol abuse, bmi ≥40 kg/m\^2 3. history of gout flare between 2 weeks before written informed consent and immediately before randomization 4. any cardiovascular abnormalities that might affect the study 5. prior or planned treatment with xanthine oxidase inhibitors, uricosuric agents, or uricolytic agents 6. prior or planned treatment with drugs acting on human uric acid transporter 1 or diuretics 7. prior or planned treatment with intravenous and oral high dose systemic corticosteroids, mercaptopurine, azathioprine, or theophylline 8. hypersensitivity to the ip (epaminurad or febuxostat) 9. pregnant or lactating woman.
quality of life in ventilator-dependant neuromuscular patients

Conditions: Neuromuscular Diseases; Respiration, Artificial; Tracheostomy; Noninvasive Ventilation; Quality of Life

Summary: this study aims at evaluating the quality of life of patients with slowly progressive neuromuscular disorders who are dependant on mechanical ventilation (daily usage ≥ 16h).


Eligibility criteria:
inclusion criteria: * patients with slowly progressive neuromuscular disorder (nmd), non walking * patients dependant on mechanical ventilation (daily usage ≥ 16h) for at least 1 year before inclusion * aged ≥ 18 yo * consent for participation * affiliated to a social security regime exclusion criteria: * patients with medically non-stable nmd: fever, acute respiratory infection, organ decompensation * patients with significant cognitive impairment (inability to read and/or incomprehension of questions) * patients with fast-evolving neuromuscular disease * patients declining to participate in the study * patients under guardianship and/or trusteeship * pregnant women
safety and efficacy study of trabectedin for the treatment of localized myxoid / round cell liposarcoma

Conditions: Liposarcoma,Myxoid

Summary: the purpose of this study is to evaluate the safety and efficacy of trabectedin for the treatment of localized (non-metastatic) myxoid / round cell liposarcoma (malignant tumor derived from primitive or embryonal lipoblastic cells).

this is an open-label (all people know the identity of the intervention), prospective (study following participants forward in time), multicenter (when more than one hospital or medical school team work on a medical research study) study of trabectedin for the treatment of localized myxoid / round cell liposarcoma (mrcl). trabectedin will be given at 1.5 milligram per meter square (mg/m\^2) over a 24-hour intravenous (iv) infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles along with dexamethasone 20 mg iv which will be given within 30 minutes before start of each trabectedin iv infusion. participants whose myxoid/round cell liposarcoma (mrcl) do not progress at the end of the neoadjuvant treatment will be followed every 6 weeks for disease progression or until 6 months post definitive surgery, in the absence of unacceptable toxicity and/or disease progression. efficacy will be assessed by determining the pathologic complete response (pcr) rate assessed in the tumor surgical specimen by a central pathology review. participants' safety will be monitored throughout the trial.

Eligibility criteria:
inclusion criteria: * pathological diagnosis of myxoid / round cell liposarcoma (mrcl) and availability of pathology specimens for central review and pharmacogenomic studies * clinical evidence of locally advanced (stage iii), non-metastatic tumor, including locally recurring disease after initial surgery * measurable disease (by response evaluation criteria in solid tumors \[recist\]) * no prior chemotherapy or radiation (except for adjuvant post-operative radiotherapy) * eastern cooperative oncology group (ecog) performance status (ps) 0-2 exclusion criteria: * known hypersensitivity to any of the components of the trabectedin intravenous (iv) formulation or dexamethasone * pregnant or lactating women and women of reproductive potential who are not using effective contraceptive methods * history of another neoplastic disease (except basal cell carcinoma or cervical carcinoma in situ adequately treated) unless in remission for 5 years or longer * known distant metastases * other serious illnesses such as congestive heart failure or angina pectoris, myocardial infarction within 1 year before enrollment, uncontrolled arterial hypertension or arrhythmias

Keywords: myxoid liposarcoma trabectedin dexamethasone